The original developer of Dacomitinib (Vizimpro) is Pfizer Inc. of the United States. It is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, widely used in the treatment of metastatic non-small cell lung cancer (NSCLC) with positive EGFR mutations. Then, how to purchase Dacomitinib?

How to Purchase Dacomitinib

For patients, purchasing Dacomitinib requires attention to the drug's source, price, and purchase convenience.

Purchase Through Formal Channels

Patients can purchase Dacomitinib through formal pharmacies or hospital pharmacies. This purchase method ensures the reliability of the drug's quality and source, avoiding the risk of counterfeit or substandard drugs.

Overseas Drug Purchase Options

In addition to domestic channels, patients may also consider purchasing Dacomitinib from overseas. Overseas versions of the drug may include Pfizer's original Dacomitinib exported to India, as well as generic versions such as those produced by Everest Pharmaceuticals (Bangladesh) and Lucius Pharmaceuticals (Laos). The prices of these versions may vary depending on the region and version.

Precautions

When purchasing Dacomitinib, patients need to pay attention to information such as the drug's batch number and expiration date. Since Dacomitinib is a prescription drug, it must be purchased with a prescription issued by a doctor.

Therapeutic Effects of Dacomitinib

Dacomitinib has shown significant efficacy in the treatment of metastatic NSCLC with positive EGFR mutations.

Clinical Trial Results

Clinical trials have shown that Dacomitinib achieves favorable efficacy in the treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletion or exon 21 L858R substitution mutation. After receiving Dacomitinib treatment, patients' conditions are effectively controlled, and their survival time is prolonged.

Mechanism of Action

Dacomitinib inhibits the activity of EGFR tyrosine kinase, blocking the signal transduction pathways for tumor cell growth and proliferation, thereby achieving the inhibitory effect on tumor cells. Additionally, Dacomitinib has the property of a pan-HER inhibitor, which can act on multiple targets such as EGFR, HER2, and HER4 simultaneously, enhancing its anti-tumor effect.

Management of Adverse Reactions

Although Dacomitinib has good therapeutic effects, some adverse reactions may occur during its use. Common adverse reactions include diarrhea, rash, and paronychia. For these adverse reactions, patients need to consult a doctor in a timely manner and take corresponding management measures.

Usage and Dosage of Dacomitinib

Correct use of Dacomitinib is crucial for exerting its therapeutic effects.

Recommended Dosage and Administration

The recommended dosage of Dacomitinib is 45mg, taken orally once a day. Patients may choose to take it with or without food. To maintain a stable concentration of the drug in the body, patients should take Dacomitinib at the same time every day.

If a patient experiences vomiting or misses a dose of Dacomitinib, there is no need to take an additional dose or make up for the missed dose. Instead, the patient should continue to take the next dose as originally scheduled. This avoids adverse reactions caused by excessive accumulation of the drug in the body.